APVO - Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

Aptevo Therapeutics ([[APVO]] +3.8%) shared positive data from a Phase 1 dose-escalation study designed to evaluate APVO436 in the treatment of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS).The trial involving 46 patients with AML or myelodysplastic syndromes, met its primary endpoint of finding the dose level for late-stage studies, the company said.Aptevo’s lead candidate based on ADAPTIR technology was generally well tolerated with a favorable side effects profile.The company also highlighted the absence of severe or prolonged neutropenia, a potentially serious effect linked to CD123-targeting therapies. Aptevo intends to submit the results later this year for publication."We remain confident about the breakthrough potential of APVO436 and look forward to sharing interim data from Part 2 of our study later this year,” Marvin White, CEO of Aptevo noted.In November, the company announced an additional complete remission in the Phase 1 trial.

For further details see:

Aptevo meets primary endpoint in early-stage trial for blood cancer therapy